Allspring Global Investments
CTXR icon

Allspring Global Investments’s Citius Pharmaceuticals CTXR Stock Holding History

Allspring Global Investments’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-4,457
Closed -$76.3K – 2340
2023
Q3 		$76.3K Buy
+4,457
New +$106K ﹤0.01% 2108
2022
Q2 		– Sell
-20,742
Closed -$928K – 2741
2022
Q1 		$928K Sell
20,742
-119
-0.6% -$4.7K ﹤0.01% 1921
2021
Q4 		$803K Buy
+20,861
New +$946K ﹤0.01% 2065

Other funds holding CTXR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Allspring Global Investments's CTXR Position: Q4 2023 in Review

Allspring Global Investments sold out of Citius Pharmaceuticals (CTXR) in Q4 2023, closing a stake of 4,457 shares — an estimated $76.3K sold.

Allspring Global Investments first reported a position in CTXR in Q4 2021 and held it in 3 quarters. The position peaked at $928K in Q1 2022. 74 funds tracked by Wall St. Rank hold CTXR as of Q4 2023.

  • Allspring Global Investments reported no remaining Citius Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Allspring Global Investments sold 4,457 Citius Pharmaceuticals shares in Q4 2023, an estimated $76.3K.
  • Allspring Global Investments first reported a position in Citius Pharmaceuticals in Q4 2021 and held it in 3 quarters.
  • Allspring Global Investments's Citius Pharmaceuticals position peaked at $928K in Q1 2022.
  • 74 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q4 2023.

Based on Allspring Global Investments's 13F filing for Q4 2023, filed 25 Jan 2024.